

## Claims:

1. A cardiotonic pharmaceutical composition having enhanced therapeutical width comprising (a) an active ingredient having the effect of digitalis and (b) a cGMP phosphodiesterase inhibitor and one or more conventional carrier(s).
2. A pharmaceutical composition of Claim 1 in which the active ingredient having the effect of digitalis is digoxin or ouabain.
3. A pharmaceutical composition of Claim 1 in which the cGMP phosphodiesterase inhibitor is cicletanine, vinpocetine, sildenafil or zaprinast or, if chemically possible, a pharmaceutically suitable acid addition salt thereof.
4. A pharmaceutical composition of Claim 1 comprising (a) digoxin and (b) cicletanine or a pharmaceutically suitable acid addition salt thereof.
5. Use of a cGMP phosphodiesterase inhibitor for the preparation of a pharmaceutical composition enhancing the therapeutical width of an active ingredient having the effect of digitalis.
6. The use of Claim 5 in which the cGMP phosphodiesterase inhibitor is cicletanine, vinpocetine, sildenafil or zaprinast or, if chemically possible, a pharmaceutically suitable acid addition salt thereof.
7. The use of Claim 6 in which the cGMP phosphodiesterase inhibitor is cicletanine or a pharmaceutically suitable acid addition salt thereof.

14

8. A method for enhancing the therapeutical width of an active ingredient having the effect of digitalis in which a patient being in need of a cardiotonic treatment with an active ingredient having the effect of digitalis is treated, in addition to  
5 the active ingredient having the effect of digitalis, also with a cGMP phosphodiesterase inhibitor.

10

15

20

25